Over recent years, hip resurfacing has been performed in young, active patients, including women in their child bearing years. Current work investigating the transplacental passage of metal ions (cobalt and chromium) suggests significant passage of ions across the placenta in mothers with metal on metal hip resurfacing. In vitro studies show that cobalt and chromium can create DNA and chromosome damage in human cells. The consequences of this ion transfer on the child during fetal development and thereafter have not been fully quantified. We report on 3 patients with metal on metal hip resurfacings who had the prosthesis in situ during pregnancy. Our data show that umbilical cord blood chromium levels are under a quarter of the maternal serum levels. Cord blood cobalt levels are approximately half that of maternal blood. All 3 children are healthy. Although there was transplacental passage of ions, there was no significant effect on the child in these cases. We did not show any teratogenic effect of metal ions on the child, and this is consistent with the reported literature.

Download full-text PDF

Source
http://dx.doi.org/10.5301/HIP.2012.9100DOI Listing

Publication Analysis

Top Keywords

transplacental passage
12
metal ions
12
hip resurfacing
12
passage metal
8
cobalt chromium
8
passage ions
8
metal metal
8
metal hip
8
cord blood
8
ions child
8

Similar Publications

Prenatal toxicity of L-mimosine in Wistar rats.

Toxicon

December 2024

Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, S.P., Brazil; Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo (ICAQF-UNIFESP), Diadema, S.P., Brazil. Electronic address:

L-Mimosine is the main active component of the plant Leucaena leucocephala. Due to its metal-chelating mechanism, it interacts with various metabolic pathways in living organisms, making it a potential pharmacological target, although it also leads to toxicity. The present study aimed to investigate the transplacental passage of L-mimosine and its effects on embryofetal development.

View Article and Find Full Text PDF

Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy.

Obstet Gynecol

January 2025

Division of Pulmonary and Critical Care Medicine, the Division of Pediatric Pulmonology, and the Division of Maternal Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Article Synopsis
  • New medications called highly effective modulator therapy are improving health for many people with cystic fibrosis (CF), leading to more pregnancies among these individuals.
  • The safety of these medications during pregnancy is unclear, as limited data show potential risks, such as health declines in patients when therapy is stopped and possible cataract development in offspring.
  • Ongoing studies are expected to shed light on these safety concerns, highlighting the importance of thorough counseling for people with CF considering pregnancy.
View Article and Find Full Text PDF

Gestational pemphigoid is a rare, autoimmune, subepidermal bullous disease with an incidence of 1 in 50,000 pregnancies, displaying itself through pruritic erythema and urticarial papules and plaques that evolve into tense bullae. Histopathological findings consist of subepidermal vesicles with perivascular eosinophils and lymphocytes, and direct immunofluorescence reveals C3 complement and, more rarely, IgG in a linear band along the basement membrane. The course is usually self-limiting within 6 months after delivery but, later, can be triggered by subsequent pregnancies, menstruation, or treatment with oral contraceptives.

View Article and Find Full Text PDF

Alloimmunization in Pregnancy: Implications for the Fetus and Neonate.

Neoreviews

November 2024

Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Evanston Hospital - Endeavor Health, University of Chicago Pritzker School of Medicine, Evanston, IL.

Article Synopsis
  • Blood group alloimmunization happens when a pregnant woman develops antibodies against a blood type that her fetus has but she doesn't, usually due to fetal-maternal bleeding or blood transfusions.
  • To prevent maternal alloimmunization, it's crucial to implement effective strategies before antibodies are formed, as this can lead to serious complications for the fetus.
  • Proper management of alloimmunization in pregnant patients should follow established protocols, utilizing current evaluation and treatment methods to ensure the safety of both the mother and the baby.
View Article and Find Full Text PDF

Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!